Nature

News

A new technology developed at Caltech represents a breakthrough in DNA synthesis, essentially allowing de novo sequence creation.

News

Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.